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http:WHAT THIS PAPER ADDS
The aim of this study was to investigate the effects of the vasodilating b-blocker nebivolol and the
cardioselective b-blocker metoprolol on nitric oxide levels at vascular graft endothelium and vasa vasorum
compared to controls in patients undergoing coronary artery bypass graft surgery. According to our results, we
think that nebivolol may be safer and preferable in order to diminish graft spasm in patients undergoing
coronary artery bypass graft surgery due to the nitric oxide-mediated vasodilating effect.Objectives: The aim of this study was to investigate the effects of the vasodilating b-blocker nebivolol and the
cardioselective b-blocker metoprolol on nitric oxide (NO) levels at vascular graft endothelium and vasa vasorum
compared to controls in patients undergoing coronary artery bypass graft surgery.
Methods: This was a prospective study. Fifty-ﬁve patients were divided into three groups: nebivolol group (group
N, n ¼ 23), metoprolol group (group M, n ¼ 16), and control group (group A, n ¼ 16). Group N received nebivolol
5 mg once daily, and group M received metoprolol 50 mg once daily for 15 days in the preoperative period.
Control patients did not use b-blocker therapy. Tissue samples of both left internal mammary artery (LIMA) and
saphenous vein grafts were investigated for NO activity using immunohistochemical methods.
Results: Demographic characteristics and risk factors were similar between groups. We observed the highest NO
activity in group N in both endothelial and vasa vasorum samples of LIMA and saphenous veins. NO activity of
metoprolol group was similar to controls.
Conclusions: According to our results, we think that nebivolol may be safer and preferable in order to diminish
graft spasm in patients undergoing coronary artery bypass graft surgery due to the NO-mediated vasodilating
effect.
 2013 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.
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Ischemic heart disease occurs as a result ofmismatch between
myocardial oxygen demand and vascular supply. Coronary
artery bypass graft (CABG) surgery is a widely utilized treat-
ment of ischemic heart disease depending on the clinical
condition. However, graft spasm, especially in arterial con-
duits, and graft stenosis still creates a major problem in pa-
tients undergoing CABG surgery.1 Graft spasm can present
with angina, acute hemodynamic collapse, ST segment
elevation, or ventricular ﬁbrillation, or a combination of these
additional factors. Insufﬁcient blood ﬂow through arterial
graftsmay also cause a “hypoperfusion syndrome”manifestedresponding author. G. Ilhan, Recep Tayyip Erdogan University,
of Medicine, Department of Cardiovascular Surgery, Islampas¸a Mah,
Rize, Turkey.
il address: drgknilhan@yahoo.com (G. Ilhan).
-5884/$ e see front matter  2013 Published by Elsevier Ltd on
of European Society for Vascular Surgery.
//dx.doi.org/10.1016/j.ejvs.2013.11.003by left ventricular failure, increasing pulmonary wedge pres-
sure, and by cardiac arrest. According to the literature, its
incidence varies between 0.8 and 1.3%.2 However, the inci-
dence andmortality ratesmaybeunderestimatedbecause it is
mainly the surviving cases that are reported, and an exact
diagnosis can only be achieved with coronary angiography.2
b1-adrenergic receptor blockers have become a hallmark
in the management of patients after acute myocardial
infarction.3 In contrast to conventional selective b1 adren-
ergic receptor antagonists such as metoprolol-succinate, the
selective b1 adrenergic receptor blocker nebivolol has been
shown to possess additional actionsdstimulating endo-
thelial cell nitric oxide (NO) production, in particular, which
is thought to be mediated by b3-receptor activation and by
interaction with the estrogen receptor.3 The release of the
endothelium-derived relaxing factor NO has been suggested
to mediate vasodilatory properties of nebivolol because
nebivolol-induced vasodilation is almost completely blocked
by inhibitors of NO synthase.4
Table 1. Demographic and clinical characteristics of patients.
Group Aa Group Mb Group Nc p
Gender (M/F) 9/7 12/4 10/13 .14
Age (y) 64 
8.93
63.2 
9.13
60.1 
1.7
.63
Hypertension
(mmHg)
6/16
(37.5%)
7/16
(43.8%)
14/23
(60.8%)
.31
Diabetes
mellitus
9/16
(56.2%)
6/16
(37.5%)
7/23
(69.6%)
.26
Hyperlipidemia 7/16
(43.8%)
10/16
(62.5%)
13/23
(56.5%)
.55
Number of
coronary
grafts (n ¼ 1)
2 0 7 .09
Number of
coronary
grafts (n > 1)
14 16 16 .43
Note. M ¼ male; F ¼ female.
a Control group.
b Metoprolol group.
c Nebivolol group.
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following treatment with nebivolol have been demon-
strated in peripheral macrovessels and in human coronary
microvessels.5 In addition, nebivolol has been shown to
cause an increase in stroke volume, associated with a
reduction in vascular resistance, resulting in a maintained
cardiac output despite reduced heart rate.6 These different
effects of NO, resulting in increasing blood ﬂow and
considerable advantages in terms of the hemodynamic
proﬁle on cardiac output, may also contribute to graft
spasm after CABG surgery. However, this activity seems not
to be a class effect of b-blockers. Yet, no clinical data on
CABG patients are available, but a rabbit model of carotid
venous bypass grafting indicates that nebivolol might
decrease the development of intimal hyperplasia.7
The aim of this study was to investigate the effects of the
vasodilating b-blocker nebivolol and the cardioselective b-
blocker metoprolol on NO levels at vascular graft endo-
thelium and vasa vasorum compared with controls in pa-
tients undergoing CABG surgery.
MATERIALS AND METHODS
This study was approved by the local institutional review
board. Written informed consent was obtained from all
participants. Fifty-ﬁve consecutive patients who underwent
CABG surgery between January and March 2007 were
randomly divided into three groups by simple randomiza-
tion constructed with tables of random numbers: nebivolol
group (group N, n ¼ 23), metoprolol group (group M,
n ¼ 16), and control group (group A, n ¼ 16). Group N
received nebivolol 5 mg once daily, and group M received
metoprolol 50 mg once daily for 15 days in the preoperative
period. Control patients did not use b-blocker therapy.
Tissue samples of both left internal mammary artery (LIMA)
and saphenous vein grafts were investigated for NO activity
using immunohistochemical methods.
Patient selection
Patients were evaluated by physical examination, laboratory
tests, transthoracic echocardiography, electrocardiography,
and coronary angiography. Hypertension was deﬁned as a
mean systolic blood pressure 140 mmHg, diastolic blood
pressure 90 mmHg, and/or use of antihypertensive
medications. Hyperlipidemia was deﬁned as total choles-
terol level >240 mg/dL (6.2 mmol/L), the current use of
lipid-lowering treatment, or both. Patients with New York
Heart Association (NYHA) class IV heart failure, left ven-
ticular ejection fraction 30%, previous CABG surgery, and
patients older than 75 years, requiring emergency surgery
and inotropic support were excluded. Patients having
additional cardiac (valvular or congenital) and systemic
(chronic obstructive pulmonary disease, and renal and he-
patic failure) pathologies were also excluded.
Surgery
Anesthetic technique was standard for all patients. General
anesthesia and intratracheal intubation were done. Mediansternotomy was performed under general anesthesia. LIMA
was prepared in suitable patients. Saphenous veins were
readied in patients requiring more than one graft. Vascular
samples of 1 cm length were taken from LIMA and saphe-
nous vein grafts prior to systemic heparin administration
during either conventional or off-pump CABG surgery.
Venous or arterial grafts other than LIMA and saphenous
veins were not used. Following sampling surgical procedure
was completed as usual. Surgical technique (off-pump or
conventional) were not taken into consideration.Immunohistochemistry
Sampled vessels were preserved in 10% formalin solution at
room temperature. Afterwards samples of vascular wall and
vasa vasorum were evaluated for NO activity. Immunohis-
tochemical staining was performed using the goat Immu-
noCruz Staining System (sc-2053; Santa Cruz Biotechnology,
Santa Cruz, CA, USA). Primary antibody was inducible nitric
oxide synthase epitope-speciﬁc rabbit antibody (0.5 mL for
200 ng/mL). Samples were evaluated using light micro-
scopes after preparation. NO activity was scored according
to histopathological ﬁndings.
Immunohistochemical expression was quantiﬁed and
scored by assessing a proportion of percentage as an in-
tensity score according to Allred’s scoring protocol.8 The
intensity of the immunostaining in the arteries was graded
semiquantitatively from 0 to 2, with 0 corresponding to the
absence of staining, 1 corresponding to the intermediate
staining, and 2 representing strong staining. The grading
was performed by a single investigator, who was unaware of
the clinical and hemodynamic data.Statistical analysis
Data were analyzed using SPSS version 13.0 for Windows
(SPSS, Chicago, IL, USA). A normal distribution of the quanti-
tative data was checked using the KolmogoroveSmirnov test.
Table 2. Nitric oxide (NO) activity in endothelium and vasa vasorum of left internal mammary artery (LIMA) grafts.
Groups Grade Group Aa Group Mb Group Nc p
Endothelial NO activity of LIMA grafts 0 16 (100%) 16 (100%) 11 (55.0%) 1.00 (A vs. M)
1 0 (0%) 0 (0%) 2 (10.0%) .002 (A vs. N)
2 0 (0%) 0 (0%) 7 (35.0%) .002 (M vs. N)
Vasa vasorum NO activity of LIMA grafts 0 12 (75.0%) 14 (87.5%) 2 (10.0%) .81(A vs. M)
1 2 (12.5%) 2 (12.5%) 6 (30.0%) .001(A vs. N)
2 2 (12.5%) 0 (0%) 12 (60.0%) .001(M vs. N)
a Control group.
b Metoprolol group.
c Nebivolol group.
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andnon-parametric testswere applied to data ofquestionably
normal distribution.The distribution of categorical variables in
both groups was compared using Pearson’s chi-square test,
continuity correction, and Fisher’s exact tests. Data are
expressed as mean  SD or percentages, as appropriate.
Statistical signiﬁcance was assumed to be p <.05.
RESULTS
Demographic characteristics of patients
Fifty-ﬁve patients (31 men, 24 women) were included in the
study. Demographic characteristics are presented in Table 1.
There were no statistically signiﬁcant differences between
three groups regarding age, gender, and presence of car-
diovascular risk factors or number of coronary artery
anastomosis.
Immunohistochemical ﬁndings
We evaluated 45 saphenous vein and 52 LIMA graft samples
during the study.
Endothelial NO activity of LIMA grafts. NO activity was
absent at LIMA endothelium at all patients from control and
metoprolol groups, and 55% of patients from nebivolol
group. However, 10% had grade 1 and 35% had grade 2 NOFigure 1. Immunohistochemical ﬁndings among groups. (A) Grade 0 n
internal mammary artery (LIMA) (20 magniﬁcation, immunohistoch
magniﬁcation, immunohistochemistry). (C) Grade 1 NO activity at vasa
Grade 2 NO activity at endothelium of saphenous vein (20 magniﬁ
vasorum of saphenous vein (20 magniﬁcation, immunohistochemistractivity in group N (Table 2). Nebivolol group had the
highest activity among groups (p ¼ .002) (Fig. 1).
Vasa vasorum NO activity of LIMA grafts. Similarly, NO
activity was highest in nebivolol group, which was statisti-
cally more signiﬁcant than groups M and A (p ¼ .001). NO
activity was comparable in groups M and A (Fig. 1).
Endothelial NO activity of saphenous vein grafts. Patients
receiving nebivolol treatment had the highest NO activity
(grades 1 and 2), which was statistically signiﬁcant
compared with both groups M and A (p ¼ .014). NO activity
was similar between groups M and A (Fig. 1; Table 3).
Vasa vasorum NO activity of saphenous vein grafts. Even
though groups M and A had slightly increased NO activity,
overall activity was signiﬁcantly higher in group N compared
with the other two groups (p ¼ .002) (Fig. 1; Table 3).DISCUSSION
We investigated the effects of the vasodilating b-blocker
nebivolol and the cardioselective b-blocker metoprolol on
NO levels at vascular graft compared to controls in patients
undergoing CABG surgery. We demonstrated that patients
receiving nebivolol 5 mg once daily showed higher NO ac-
tivity at both endothelium and vasa vasorum of LIMA thanitric oxide (NO) activity at endothelium and vaso vasorum of left
emistry). (B) Grade 2 NO activity at endothelium of LIMA (20
vasorum of LIMA (20 magniﬁcation, immunohistochemistry). (D)
cation, immunohistochemistry). (E) Grade 2 NO activity at vasa
y).
Table 3. Nitric oxide (NO) activity at endothelium and vasa vasorum of saphenous grafts.
Groups Grade Group Aa Group Mb Group Nc p
Endothelial NO activity of saphenous vein grafts 0 15 (93.8%) 12 (100%) 10 (58.8%) .50 (A vs. M)
1 0 (%0) 0 (%0) 6 (35.3%) .001 (A vs. N)
2 1 (6.3%) 0 (0%) 1 (5.9%) .001 (M vs. N)
Vasa vasorum NO activity of saphenous vein
grafts
0 10 (62.5%) 8 (66.7%) 1 (5.9%) .50 (A vs. M)
1 4 (25.0%) 3 (25.0%) 6 (35.3%) .002 (A vs. N)
2 2 (12.5%) 1 (8.3%) 10 (58.8%) .002 (M vs. N)
a Control group.
b Metoprolol group.
c Nebivolol group.
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be beneﬁcial for improving graft patency and survival.
The endothelium modulates the tone of the underlying
vascular smooth muscle cells by producing relaxing factors,
mainly NO and prostacyclin, and constricting factors, such
as endothelin. Endothelial dysfunction is a common feature
of cardiovascular diseases. Therefore, it seems highly
desirable to target therapeutic strategies towards the
improvement (i.e., repair) of endothelial function.9
Metoprolol and nebivolol have a similar potency in
binding to b1- and b2-adrenergic receptors, but nebivolol,
in particular, is suggested to exert NO-releasing effects,
probably via reduction of reactive oxygen species, whereas
metoprolol is lacking this pleiotropic effect on vascular
function.10 The use of third-generation b-blockers with
additional vasodilatory properties, in the treatment of hy-
pertension, heart failure and ischemic syndromes is
increasing.10 In contrast with most of the b-adrenoreceptor
blockers, nebivolol has vasodilatory properties that are
dependent on the presence of the endothelium and are
associated with activation of endothelial nitric oxide syn-
thase.11 There is evidence that nebivolol, in addition to its
b1-adrenoreceptor blocking effects, can stimulate endo-
thelial NO production, which has been suggested to be
mediated, at least in part, by a b3-agonistic effect.12,13
Furthermore, nebivolol has been suggested to exert anti-
oxidant effects that have been attributed, at least in part,
to prevention of nicotinamide adenine dinucleotide phos-
phate oxidase activation in response to hyperlipidemia or
angiotensin II.5,14
There is evidence that b3-adrenoreceptor stimulation
may be involved in the release of endothelial NO induced by
nebivolol.15 Conversely, there are reports in the literature
on the activation of estrogen receptors and the implications
of this in the vascular effects of nebivolol, especially with
respect to the anti-atherosclerotic property of nebivolol,
which inhibits smooth muscle growth.16 Broeders et al.3
showed that in vivo metabolites of nebivolol increased
NO activity and endothelial calcium concentrations in vitro
vascular segments. Several other studies also proved that
nebivolol induced vasodilation, which could be inhibited by
N-monomethyl-L-arginine.3,11 Ignarro et al.17 showed that
the mechanism of nebivolol-induced vasodilation is through
NO and the cyclic guanosine monophosphate receptor.Goldstein et al.18 compared the effect of nebivolol versus
atenolol in patients undergoing CABG surgery and found
that atenolol increased both systemic vascular resistance
and cardiac index, whereas nebivolol increased cardiac in-
dex while lowering systemic vascular resistance. Our data
suggest that nebivolol increased NO activity in vascular graft
endothelium. Moreover, the highest NO grades were
observed in group N. Interestingly, NO activity was absent in
LIMA endothelium in all patients in group M and 55% of
patients from group N. This may indicate that regional dif-
ferences may exist regarding b-adrenoreceptor signaling in
endothelial cells.
A strong limitation of the present study has to be
expressed. b-Blockers have been compared concerning hard
end-points, and it was recently shown that carvedilol was
superior to both metoprolol and nebivolol in reducing
mortality in heart failure and patients with myocardial
infarction.19 Another limitation is the absence of data on
blood pressures (both before and after the initiation of
treatment with the two b-blockers) and low-density lipo-
protein cholesterol levels in the different groups.
In conclusion, we think that the documented NO activity
in patients younger than 75 years with NYHA IeIII heart
failure, left ventricular ejection fraction >30%, and no his-
tory of additional cardiac and systemic disease undergoing
CABG surgery is very important because higher NO activity
in graft endothelium and vasa vasorum may reduce
ischemia, graft spasm, and, perhaps, graft stenosis. As b-
blocker agents are widely used in patients undergoing CABG
surgery, nebivolol may be safer and preferable in order to
diminish graft spasm in patients undergoing CABG surgery
due to the NO-mediated vasodilating effect.
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